Literature DB >> 25640813

Daily aspirin may reduce mortality from prostate cancer with risk of high recurrence.

Mary Kay Barton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25640813     DOI： 10.3322/caac.21263

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN： 0007-9235            Impact factor:   508.702


× No keyword cloud information.
  5 in total

Review 1.  Glycogen synthase kinase-3: a potential preventive target for prostate cancer management.

Authors:  Benyi Li; James Brantley Thrasher; Paul Terranova
Journal:  Urol Oncol       Date:  2015-06-04       Impact factor: 3.498

Review 2.  Current status and future directions of cancer immunotherapy.

Authors:  Hongming Zhang; Jibei Chen
Journal:  J Cancer       Date:  2018-04-19       Impact factor: 4.207

3.  Aspirin Exposure and Mortality Risk among Prostate Cancer Patients: A Systematic Review and Meta-Analysis.

Authors:  Lai Lai Fan; Cheng Peng Xie; Yi Ming Wu; Xi Jie Gu; Ying He Chen; Yi Jun Wang
Journal:  Biomed Res Int       Date:  2019-04-03       Impact factor: 3.411

4.  Regular use of aspirin is associated with a lower cardiovascular risk in prostate cancer patients receiving gonadotropin-releasing hormone therapy.

Authors:  Wei-Ting Chang; Chon-Seng Hong; Kun-Lin Hsieh; Yi-Chen Chen; Chung Han Ho; Jhih-Yuan Shih; Wei-Chih Kan; Zhih-Cherng Chen; You-Cheng Lin
Journal:  Front Oncol       Date:  2022-09-12       Impact factor: 5.738

Review 5.  TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy.

Authors:  Adam S Dayoub; Rolf A Brekken
Journal:  Cell Commun Signal       Date:  2020-02-22       Impact factor: 5.712
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.